Homologous recombination deficiency (HRD) scores and hormone receptor subtype are predictive of immunogenicity in BRCA1/2 breast cancers and may aid in designing optimal immune therapeutic strategies, as suggested by Kraya et al. [126]. Here, NR4A1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.